
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only** (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under §240.14a-12

Eleven Biotherapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

August 5, 2016

*****IMPORTANT REMINDER: PLEASE VOTE TODAY*****

Dear Stockholder:

We have previously mailed you information relative to the Special Meeting of Stockholders of Eleven Biotherapeutics, Inc. to be held on August 15, 2016.

According to our latest records, we have not yet received your vote. The Special Meeting is only a short time away, and therefore it is important that you vote the enclosed proxy card today. The proxy statement contains disclosure information about the proposal(s) for which votes or voting instructions have been solicited.

Only your active vote will ensure that your shares will be represented at the meeting in accordance with your desires.

Your vote is very important no matter how many shares you own.

You may view the meeting documents and vote online today using the Control Number that appears on the enclosed proxy card.


Please sign and date the enclosed proxy card (or follow the telephone & internet instructions) today. In the event that more than one vote is received from you, only the one bearing the latest date will be counted, as it automatically revokes all prior proxies.

Thank you for your cooperation and continued support.

Sincerely,

A handwritten signature in black ink, appearing to read "Daniel S. Lynch".

Daniel S. Lynch
Chairman of the Board of Directors

A handwritten signature in black ink, appearing to read "Abbie C. Celniker".

Abbie C. Celniker, Ph.D.
Chief Executive Officer, Director

***** Please Vote Today*****

215 First Street, Suite 400, Cambridge, MA 02142

PHONE: 617-871-9911
FAX: 617-858-0911